168 related articles for article (PubMed ID: 37120858)
41. PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints.
He T; Liu R; Liu M; Lin J
J Biopharm Stat; 2022 Jul; 32(4):567-581. PubMed ID: 36000260
[TBL] [Abstract][Full Text] [Related]
42. Bayesian borrowing from historical control data in a vaccine efficacy trial.
Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
[TBL] [Abstract][Full Text] [Related]
43. Evaluating hybrid controls methodology in early-phase oncology trials: A simulation study based on the MORPHEUS-UC trial.
Wang G; Poulin-Costello M; Pang H; Zhu J; Helms HJ; Reyes-Rivera I; Platt RW; Pang M; Koukounari A
Pharm Stat; 2024; 23(1):31-45. PubMed ID: 37743566
[TBL] [Abstract][Full Text] [Related]
44. A group-sequential randomized trial design utilizing supplemental trial data.
Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
[TBL] [Abstract][Full Text] [Related]
45. Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J
Pharm Stat; 2022 Sep; 21(5):818-834. PubMed ID: 35128780
[TBL] [Abstract][Full Text] [Related]
46. Power prior for borrowing the real-world data in bioequivalence test with a parallel design.
Huang L; Su L; Zheng Y; Chen Y; Yan F
Int J Biostat; 2021 May; 18(1):73-82. PubMed ID: 33962492
[TBL] [Abstract][Full Text] [Related]
47. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
Harari O; Soltanifar M; Verhoek A; Heeg B
Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
[TBL] [Abstract][Full Text] [Related]
48. A new basket trial design based on clustering of homogeneous subpopulations.
Krajewska M; Rauch G
J Biopharm Stat; 2021 Jul; 31(4):425-447. PubMed ID: 34236938
[TBL] [Abstract][Full Text] [Related]
49. Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes.
Fayette L; Sailer MO; Perez-Pitarch A
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1386-1397. PubMed ID: 37644910
[TBL] [Abstract][Full Text] [Related]
50. Bayesian Design for Pediatric Clinical Trials with Binary Endpoints When Borrowing Historical Information of Treatment Effect.
Jin M; Li Q; Kaur A
Ther Innov Regul Sci; 2021 Mar; 55(2):360-369. PubMed ID: 32955713
[TBL] [Abstract][Full Text] [Related]
51. Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs.
Schmidt AF; Klugkist I; Klungel OH; Nielen M; de Boer A; Hoes AW; Groenwold RH
J Clin Epidemiol; 2015 Apr; 68(4):387-96. PubMed ID: 25554520
[TBL] [Abstract][Full Text] [Related]
52. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
Chen N; Lee JJ
Biom J; 2019 Sep; 61(5):1219-1231. PubMed ID: 30506747
[TBL] [Abstract][Full Text] [Related]
53. An overview of precision oncology basket and umbrella trials for clinicians.
Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
[TBL] [Abstract][Full Text] [Related]
54. Bayesian Dynamic Borrowing of Historical Information with Applications to the Analysis of Large-Scale Assessments.
Kaplan D; Chen J; Yavuz S; Lyu W
Psychometrika; 2023 Mar; 88(1):1-30. PubMed ID: 35687222
[TBL] [Abstract][Full Text] [Related]
55. Practical basket design for binary outcomes with control of family-wise error rate.
Asano J; Sato H; Hirakawa A
BMC Med Res Methodol; 2023 Feb; 23(1):52. PubMed ID: 36849940
[TBL] [Abstract][Full Text] [Related]
56. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
Fu C; Pang H; Zhou S; Zhu J
Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
[TBL] [Abstract][Full Text] [Related]
57. An adaptive power prior for sequential clinical trials - Application to bridging studies.
Ollier A; Morita S; Ursino M; Zohar S
Stat Methods Med Res; 2020 Aug; 29(8):2282-2294. PubMed ID: 31729275
[TBL] [Abstract][Full Text] [Related]
58. Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases.
Sebastien B
J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):495-499. PubMed ID: 37148459
[TBL] [Abstract][Full Text] [Related]
59. Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring.
Wu D; Goldfeld KS; Petkova E
BMC Med Res Methodol; 2023 Jan; 23(1):25. PubMed ID: 36698073
[TBL] [Abstract][Full Text] [Related]
60. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.
Zhang W; Laird G; Chen J; Yuan Y
Stat Med; 2024 Jan; 43(1):173-183. PubMed ID: 37937591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
